1. Comparative assessment of adverse reaction reports submitted to WHO-UMC by the Turkish Pharmacovigilance Center (TUFAM) through 2008/2009/2010;Aykac;Drug Saf,2011
2. Ministry of Health, General Directorate of Pharmaceuticals and Pharmacy 2011 Guidelines on risk management systems ( Risk yönetim sistemleri kilavuzu ), Ministry of Health, General Directorate of Pharmaceuticals and Pharmacy http://www.iegm.gov.tr/PortalAdmin/Uploads/UnitPages/kilavuz.pdf
3. Ministry of Health, General Directorate of Pharmaceuticals and Pharmacy n.d Guidelines on biosimilar drug products, Ministry of Health General Directorate of Pharmaceuticals and Pharmacy www.iegm.gov.tr/Default.aspx?sayfa=regulations&lang=en&thelawtype=12&thelawId=218
4. Resmi Gazete 2005 Beşeri Tıbbi Ürünlerin Güvenliğinin İzlenmesi ve Değerlendirilmesi Hakkında Yönetmelik www.resmi-gazete.org/rega/beseri-tibbi-urunlerin-guvenliginin-izlenmesi-ve-degerlendirilmesi-hakkinda-yonetmelik-19199.htm
5. An important component of Turkish pharmacovigilance system: pharmacovigilance contact points;Sagis;Drug Saf,2010